Vol. 22/No. 5

As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.

Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.

Despite many diversity initiative over the past 10 years, a lack of meaningful representation of certain racial and ethnic minorities continues in the oncology workforce.

Findings from recent analyses have kindled hope that novel agents with manageable toxicity profiles may begin to bridge the gap for patients with HER2-positive metastatic breast cancer.

Devimistat, a small molecule that targets enzymes involved in cancer cell metabolism, holds promise for older patients with relapsed or refractory acute myeloid leukemia who typically have a poor prognosis with standard-of-care chemotherapy

Evolving data provide provocative support for the relevance of an optimistic vs a pessimistic perspective in influencing outcomes in serious malignant conditions.

When the coronavirus disease 2019 pandemic started upending health care services throughout the United States a year ago, the oncology community moved quickly to develop guidance on selecting therapies and setting treatment schedules for many cancers to allow for less frequent in-patient visits to clinics and infusion centers.

Trastuzumab deruxtecan represents a potential new standard of care for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.